https://scholars.lib.ntu.edu.tw/handle/123456789/524150| Title: | 2018 Guidelines of the Taiwan Society of Cardiology, Taiwan Society of Emergency Medicine and Taiwan Society of Cardiovascular Interventions for the management of non ST-segment elevation acute coronary syndrome | Authors: | Li Y.-H. YI-CHIH WANG YI-CHIH WANG Liu J.-C. Lee C.-H. Chen C.-C. Hsieh I.-C. Kuo F.-Y. Huang W.-C. Sung S.-H. Chiu C.-Z. Hsu J.-C. Jen S.-L. HWANG, JUEY-JEN Lin J.-L. The Writing Group of 2018 Taiwan Guidelines for the Management of Non ST-segment Elevation Acute Coronary Syndrome |
Issue Date: | 2018 | Publisher: | Elsevier B.V. | Journal Volume: | 117 | Journal Issue: | 9 | Start page/Pages: | 766-790 | Source: | Journal of the Formosan Medical Association | Abstract: | In Taiwan, the incidence of non-ST segment elevation acute coronary syndrome (NSTE-ACS) continues to increase in recent years. The purpose of this guideline is to help health care professionals in Taiwan to use adequate tests and treatments for management of NSTE-ACS. For rapid diagnosis, in addition to history and physical examination, 0/3 h rapid diagnosis protocol with high sensitivity cardiac troponin assay is recommended in this guideline. Dual antiplatelet and anticoagulation therapies are important parts in the initial treatment. Risk stratification should be performed to identify high risk patients for early coronary angiography. Through evaluation of the coronary anatomy and other clinical factors, the decision for coronary revascularization, either by percutaneous coronary intervention or coronary artery bypass grafting, should be decided by the heart team. The duration of dual antiplatelet therapy should be given for at least 12 months after discharge. Other secondary preventive medications are also recommended for long term use. ? 2018 |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85049739967&doi=10.1016%2fj.jfma.2018.06.002&partnerID=40&md5=01b339896c0b55e045222fc1b288d2c7 https://scholars.lib.ntu.edu.tw/handle/123456789/524150 |
ISSN: | 0929-6646 | DOI: | 10.1016/j.jfma.2018.06.002 | SDG/Keyword: | acetylsalicylic acid; antilipemic agent; biological marker; calcium channel blocking agent; clopidogrel; dipeptidyl carboxypeptidase inhibitor; fondaparinux; glycoprotein IIb; heparin; low molecular weight heparin; nitrate; oxygen; protein inhibitor; ticagrelor; troponin; anticoagulant agent; antithrombocytic agent; anticoagulant therapy; Article; assay; bleeding; cardiac imaging; cardiac patient; cardiac troponin assay; coronary angiography; coronary artery bypass graft; disease marker; dual antiplatelet therapy; early diagnosis; electrocardiography; emergency; health care personnel; high risk patient; human; ischemia; medical decision making; medical history; medical society; meta analysis (topic); multicenter study (topic); non st segment elevation acute coronary syndrome; pathophysiology; patient identification; physical examination; practice guideline; randomized controlled trial (topic); renin angiotensin aldosterone system; revascularization; risk assessment; secondary prevention; Taiwan; treatment duration; acute coronary syndrome; cardiology; classification; emergency medicine; fibrinolytic therapy; medical society; percutaneous coronary intervention; practice guideline; risk factor; standards; Acute Coronary Syndrome; Anticoagulants; Cardiology; Coronary Angiography; Emergency Medicine; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Societies, Medical; Taiwan; Thrombolytic Therapy [SDGs]SDG3 |
| Appears in Collections: | 醫學系 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.